Brief: Innate Pharma To Present Additional Efficacy Data For Monalizumab In Combination With Cetuximab

Innate Pharma SA

03/12/2020 13:31

Dec 3 (Reuters) - Innate Pharma SA  IPH.PA :
    * REG- INNATE PHARMA TO PRESENT ADDITIONAL EFFICACY DATA FOR
MONALIZUMAB IN COMBINATION WITH CETUXIMAB IN HEAD AND NECK
CANCER AT THE ESMO IMMUNO-ONCOLOGY VIRTUAL CONGRESS
    * PHASE 2 EXPANSION COHORT DATA SUPPORTS ONGOING PHASE 3
TRIAL
    * MONALIZUMAB IS A POTENTIALLY FIRST-IN-CLASS IMMUNE
CHECKPOINT
INHIBITOR TARGETING NKG2A RECEPTORS EXPRESSED ON TUMOR
INFILTRATING CYTOTOXIC CD8(+) T CELLS AND NK CELLS

Source text for Eikon:  ID:nGNE7NJGzp 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))